Optimer Pharmaceuticals, Inc.
OPTR announced today the execution of an exclusive agreement with
AstraZeneca AZN to commercialize fidaxomicin tablets for the treatment of
Clostridium difficile Infection (CDI) in South America, including Brazil,
Central America, Mexico and the Caribbean.
Under the terms of the agreement AstraZeneca is responsible for the
commercialization of fidaxomicin in the territory covered by the collaboration
and Optimer is entitled to receive an up-front payment of $1 million, up to $3
million in milestone payments upon first commercial sale in certain countries,
and up to $19 million in other milestone payments contingent on the
achievement of sales-related targets for fidaxomicin in the territory. Optimer
is further entitled to receive payments from AstraZeneca that provide a return
resulting in a double digit percent of net sales in the territory under a
fidaxomicin supply agreement.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in